Pfizer and Valneva to Seek Approval for Lyme Disease Vaccine After Trial

In Brief

A potential Lyme disease vaccine may address a longstanding gap in prevention options for the tick-borne illness.

Key Facts

• Pfizer and French partner Valneva announced plans to seek regulatory approval for their Lyme disease vaccine.
• The announcement followed a late-stage clinical trial of the vaccine.
• Pfizer reported the vaccine showed 73% effectiveness against Lyme disease in the study.
• Fewer-than-expected Lyme disease cases occurred in the study, affecting the ability to assess large-scale effectiveness.
• The vaccine targets Lyme disease, a tick-borne illness.

What Happened

Pfizer and Valneva stated they will seek regulatory approval for their Lyme disease vaccine after results from a late-stage trial showed 73% effectiveness, though the number of cases in the study was lower than anticipated.

Why It Matters

If approved, this vaccine could become the first available option for Lyme disease prevention in many years, potentially impacting public health in regions where the illness is prevalent.

What's Next

Regulatory agencies will review the approval request. Further analysis may be needed to confirm the vaccine's effectiveness due to the limited number of cases in the trial.